AURON THERAPEUTICS
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
AURON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Wellesley, Massachusetts, United States
Country:
United States
Website Url:
http://www.aurontx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
61.41 M USD
Technology used in webpage:
Google Maps U.S. Server Location
Similar Organizations
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Current Advisors List
Current Employees Featured
Founder
Investors List
DCVC Bio
DCVC Bio investment in Series A - Auron Therapeutics
Polaris Partners
Polaris Partners investment in Series A - Auron Therapeutics
Arkin Bio Ventures
Arkin Bio Ventures investment in Series A - Auron Therapeutics
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series A - Auron Therapeutics
Mubadala Capital Ventures
Mubadala Capital Ventures investment in Series A - Auron Therapeutics
Franklin Berger
Franklin Berger investment in Series A - Auron Therapeutics
Apollo Health Ventures
Apollo Health Ventures investment in Series A - Auron Therapeutics
Eli Lilly
Eli Lilly investment in Series A - Auron Therapeutics
BrightEdge Fund
BrightEdge Fund investment in Series A - Auron Therapeutics
Casdin Capital
Casdin Capital investment in Series A - Auron Therapeutics
Official Site Inspections
http://www.aurontx.com Semrush global rank: 7.61 M Semrush visits lastest month: 726
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Auron Therapeutics"
About - aurontx.com
At Agios, she also oversaw clinical operations and helped build the organization responsible for the development of two FDA-approved IDH mutant inhibitors, IDHIFA® for acute myeloid leukemia (AML) and TIBSOVO® for AML and โฆSee details»
Auron Therapeutics
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting. Newton, MA, November 5, 2024 โ Auron Therapeutics, a biotechnology company focused on developing โฆSee details»
Auron Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells.See details»
Auron Therapeutics, Inc. | LinkedIn
Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid ...See details»
Auron Therapeutics - Craft
Auron Therapeutics is a medtech company specializing in cancer formation research. It develops a machine learning platform that integrates multi-omic datasets from primary human tissue โฆSee details»
Auron Therapeutics - VentureRadar
Similar Companies: Roivant Sciences Inc. Switzerland Publicly Traded Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by โฆSee details»
Auron Therapeutics announces $48 million Series A financing to โฆ
Jul 20, 2022 Auron expands its leadership team with the appointments of David Millan, Ph.D., as Chief Scientific Officer, Thomas Graeber, Ph.D., as Chief Data Officer, Andrea Armstrong as โฆSee details»
Auron Establishes Premier Scientific Advisory Board to Support the ...
Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity, today announced the members โฆSee details»
AUTX-703 - Drug Targets, Indications, Patents - Synapse - Patsnap
Originator Organization. Auron Therapeutics, Inc. Startup. Active Organization. Auron Therapeutics, Inc. Startup. Inactive Organization-Drug Highest Phase Preclinical. First โฆSee details»
Auron Therapeutics Closes $12.75 Million Seed Financing to โฆ
WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron Therapeutics (โAuronโ), a biopharmaceutical company focused on developing differentiation therapies for treating โฆSee details»
Auron Therapeutics - Overview, News & Similar companies
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron โฆSee details»
Auron Therapeutics
Atlases to Map Cancer Cell States. We have combined a proprietary database of single cell genomic data with an AI-powered computational platform that allows us to compare healthy โฆSee details»
Auron Therapeutics Closes $12.75 Million Seed Financing to
WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron Therapeutics (โAuronโ), a biopharmaceutical company focused on developing differentiation...See details»
Auron Selects First Development Candidate for its Portfolio of โฆ
Feb 8, 2024 Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today โฆSee details»
Auron Presents New Preclinical Data for Lead Program AUTX-703 โฆ
Oct 24, 2024 Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models. AUTX-703 IND submission on track for late 2024See details»
Auron Therapeutics announces $48 million Series A financing
Jul 20, 2022 Please find more information at www.aurontx.com. CONTACT Auron Therapeutics Kate Yen, Ph.D. Founder and Chief Executive Officer [email protected]. MEDIA Katie โฆSee details»
AUR-1545 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Company showcases property-based design and optimization of orally bioavailable degraders targeting KAT2A/BNEWTON, Mass., Aug. 19, 2024 (GLOBE โฆSee details»
Auron Therapeutics announces $48 million Series A financing to โฆ
Jul 20, 2022 This type of therapy, called differentiation therapy, offers lifesaving, transformative treatments for patients and their families. Please find more information at www.aurontx.com. โฆSee details»
AUR-101 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 AUR-101: a RORฮณt inverse agonists Drug, Initially developed by Aurigene Oncology Ltd., Now, its global highest R&D status is Phase 2, Mechanism: RORฮณt inverse โฆSee details»
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH โฆ
Newton, MA, November 5, 2024 โ Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell โฆSee details»